Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 11, 2025 09:30 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and...
July 11, 2025 06:01 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Proposed Public Offering

MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public...
July 11, 2025 06:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone®...
June 16, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration...
May 28, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

MONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief...
May 14, 2025 07:04 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE...
March 28, 2025 07:00 ET | Source: Milestone Pharmaceuticals Inc.

FDA Issues Complete Response Letter for Etripamil for PSVT

CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28,...
March 20, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
March 13, 2025 07:08 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for...
March 04, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...